Objective: When a bypass fails, the options are lysis, redo bypass, or endovascular intervention. If lysis of the original bypass is not considered an option, which is betterdredo bypass or attempts at endovascular recanalization of the native system? This retrospective study examined the outcomes of native superficial femoral artery (SFA) chronic total occlusion (CTO) recanalization compared with redo bypass after failed femoropopliteal bypass.
Bypass occlusion remains a significant issue with an attendant increased mortality and morbidity. 1, 2 The options for intervention after symptomatic remain percutaneous and open thrombus removal or redo bypass. 1 A recent study by Taha et al 3 concluded that the amputation rates are comparable between endovascular techniques and open techniques. In their report, overall mortality rates were significantly higher at 30 days and 1 year in the patients requiring open intervention. In the stable patient with claudication or rest pain, or both, revision bypass rather than thrombolysis was more commonly performed. 3 An alternative strategy is to perform endovascular revascularization of the superficial femoral artery (SFA) and avoid catheter-directed thrombolysis (CDT) or redo open surgery. This retrospective study examined the outcomes of native SFA chronic total occlusion (CTO) endovascular recanalization (EV) compared with redo bypass (BP) after failed femoropopliteal bypass.
METHODS
Study design. Consecutive patients presenting with a symptomatic failed femoropopliteal bypass that underwent endovascular recanalization or bypass grafting from 2000 to 2015 were analyzed. Patients with acute limb ischemia, those requiring an emergency procedure, and those undergoing CDT or graft thrombectomy were excluded. Patient-centered outcomes of clinical efficacy (absence of recurrent symptoms, maintenance of ambulation, and absence of major amputation), amputation-free survival (AFS; survival without major amputation), and freedom from major adverse limb events (MALE; above-ankle amputation of the index limb or major reintervention: new bypass graft, jump/interposition graft revision), and objective performance goals (OPGs) were evaluated. Life-table analyses were performed to assess time-dependent outcomes. Factor analyses were performed using a Cox proportional hazard model for time-dependent variables. The requirement to obtain written informed consent was waived because patients were not directly studied and the data collection was retrospective and de-identified. Patients were drawn from both institutions. The institutional review boards approved the study.
Decision making. The reasons for not performing lysis included contraindication to lysis, a previous recent lysis attempt of the same graft, grade II ischemia, presence of an above-knee prosthetic graft, and patient preference. The reasons to choose endovascular recanalization included a shorter segment SFA lesion with a patent popliteal artery and the patient's comorbidities. The reasons to chose bypass grafting were the presence of a good great saphenous vein, TransAtlantic Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC) II D SFA occlusive lesion with flush SFA origin occlusion, an occluded popliteal artery, and poor tibial runoff. There was no pattern in the attending staff that performed either endovascular intervention or redo surgery.
Methodology. Demographics, symptoms, existing comorbid conditions, and risk factors for atherosclerosis were identified for each patient. Modifiable risk factors were identified for each patient and corrected through his or her primary care provider. 4 All patients received aspirin daily (81 mg or 325 mg) and a statin as general cardiovascular protection. Noninvasive studies (peripheral vascular resistance or duplex imaging, or both) were performed initially on all patients receiving a workup for failed femoropopliteal bypass.
The intervention was performed with the patient under systemic heparin administration to achieve an activated clotting time of 250 seconds. The technical result was assessed with completion angiography. Stents were used primarily. No covered stents were used. Patients underwent routine follow-up with duplex ultrasound imaging at 1, 3, and every 6 months after the procedure using criteria previously described. 4 During follow-up, angiography was only performed if noninvasive studies suggested restenosis/occlusion, defined as a positive duplex scan with a drop in ankle-brachial index of >0.15 and toe-brachial index of >0.1, and the patient had recurrent symptoms. 4 Median follow-up was 2.8 years (range, 0-8 years).
Definitions. Coronary artery disease was defined as a history of angina pectoris, myocardial infarction, congestive heart disease, or prior coronary artery revascularizations. The modified Lee Index was used to quantify cardiac risk (MCRI). 5 Chronic renal impairment was defined as an estimated glomerular filtration rate of <60 mL/min/ 1.73 m 2 or if the patient was on hemodialysis or peritoneal dialysis. Hypertension was defined as a systolic blood pressure >150 mm Hg or diastolic blood pressure >90 mm Hg on three occasions during a 6-month period. Hypercholesterolemia was defined as fasting serum concentrations of cholesterol >200 mg/dL, low-density lipoprotein >130 mg/dL, or triglycerides >200 mg/dL. Diabetes was defined as a fasting plasma glucose >110 mg/dL or an HbA 1c >7%. Noninsulin-dependent diabetes mellitus was defined as any patient with diabetes mellitus who did not routinely receive insulin therapy for their diabetes management. Insulin-dependent diabetes mellitus was defined as any patient with diabetes mellitus who routinely received insulin therapy. Metabolic syndrome was defined as previously described 6 (insulin resistance or impaired glucose tolerance, hypertension, dyslipidemia, and abdominal obesity), with the exception of abdominal circumference, which was not routinely recorded. We substituted a body mass index score $30.0 kg/m 2 as a positive score instead of an abdominal circumference >102 cm for men or >88 cm for women. Cerebrovascular disease was defined as a history of stroke or transient ischemic attack. Hypothyroidism was defined as a history of hypothyroidism or receiving thyroid replacement therapy. Ambulation status was categorized as independently ambulatory, ambulatory with assistance, such as a cane or a walker, wheelchair bound, or bedridden.
The TASC II classification of disease severity for femoral lesions was used to define the categories of lesions. 7 The preoperative distal runoff was scored by the number of patent tibial vessels and according to a modification of Society for Vascular Surgery (SVS) criteria used for determining bypass runoff (using the cumulative score for the distal popliteal from the knee joint to first tibial branch; maximum 9 þ 1) and each of the tibial vessels (maximum 3 each) giving a maximum possible total score of 19.
8
Pedal runoff was scored by the number of patent pedal vessels: each dorsalis pedis, lateral plantar, and medial plantar artery was assigned a score according to the reporting standards of the SVS: 0 (no stenosis >20%), 1 (21%-49% stenosis), 2 (50%-99% stenosis), 2.5 (<50% of the vessel length occluded), and 3 (>50% of the vessel length occluded). A foot score (dorsalis pedis þ medial plantar þ lateral plantar þ 1) was calculated for each foot (range, 1-10). 9 The modified Edifoligide for the Prevention of Infrainguinal Vein Graft Failure (PREVENT III) amputation risk score allocated points to each patient for the presence of dialysis (4 points), tissue loss (3 points), age $75 years (2 points), and coronary artery disease (1 point). 10 Total scores were used to stratify each patient into low-risk (#3 points), medium risk (4-7 points), and high-risk ($8 points) categories. In the Finnvasc Score system, 11 1 point was allocated for the presence of diabetes, coronary artery disease, foot gangrene, and urgent operation, and the groups were stratified into categories of 0, 1, 2, 3, or 4, with categories 3 and 4 being considered high risk. The SVS Objective Performance Goals (OPGs) were defined at 30 days and 1 year. 12 To satisfy the OPG, the upper bound of the 95% confidence interval must be the OPG or less. The 30-day OPGs were the rates of major adverse cardiovascular events (MACE; myocardial infarction, stroke or death), major adverse limb events (MALE; amputation or major reintervention defined as endovascular reintervention on the same leg, placement of new bypass graft, use of thrombectomy or thrombolysis, or major surgical revision such as a jump or interposition graft), and 30-day amputation (above-ankle amputation of the index limb).
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A death #30 days of the procedure was considered procedure-related and a perioperative death. A major complication was defined as any event, regardless of how minimal, not routinely observed after endoluminal therapy that required treatment with a therapeutic intervention or rehospitalization #30 days of the procedure. Systemic complications were those related to cardiac, pulmonary, renal, and sepsis. Lesional complications were those related to acute flow-limiting dissection, acute occlusion, perforation, and distal embolization. Local complications were those related to harvest site, surgical wounds, and the treated limb.
Preprocedural and postprocedural symptoms were defined by SVS criteria, 13 and a drop in symptom score of $1 in follow-up was considered as recurrent symptoms. Primary, assisted primary, and secondary patency rates were defined in accordance with the reporting standards of the SVS. 13 Clinical efficacy was defined as absence of recurrent symptoms, maintenance of ambulation, and limb preservation. 4 Statistical analysis. Statistical analyses were performed on an intention-to-treat basis. Measured values are reported as percentages or means 6 standard deviation. Time-dependent variables are presented using life-table analyses (mean 6 standard error of the mean). Definitions of all outcome parameters used were defined by Conte et al. 12 Analyses were performed using JMP 9.0 software (SAS Institute, Inc, Cary, NC).
RESULTS
Patient population. A total of 104 patients (69% male; average age, 65 years) underwent endovascular recanalization (EV group; n ¼ 40) or bypass grafting (BP group; n ¼ 64) after presentation with symptomatic occlusion of a previous placed femoropopliteal bypass graft. All had an origin from the common femoral artery. Seventy-nine percent of these grafts were to the aboveknee popliteal artery, and the remainder were to the below-knee popliteal artery. Eighty-one percent of the conduits were prosthetic, predominantly polytetrafluoroethylene, and the rest were single-segment great saphenous vein. Sixty-two percent of the patients had undergone ipsilateral endovascular interventions before their bypass placement (median, 2; range 1-5), and 57% had undergone an ipsilateral endovascular intervention (angioplasty, stenting, or lysis) on the bypass graft before its index failure. The grafts were a median age of 7 years (range, 3-11 years), and 91% had initially been placed for claudication. There was a positive association with the original prosthetic graft placed for claudication and presentation with rest pain (P ¼ .006 by Fisher exact test). Demographics and comorbidities for the two patient groups are reported in Table I . Patients undergoing BP reported a lower incidence of coronary artery disease; however, the difference in the overall Modified Cardiac Risk Index (MCRI) or the proportion of patients in the high-risk MCRI category between the groups was not significant. The groups were similar in many respects, except for a history of smoking, presence of hypertension, and statin use ( Table I ). The distribution of preoperative ambulatory status was equivalent in both groups. Use of the Modified PREVENT III index or the Finnvasc score to quantify the risk of amputation showed most of the patients were low to medium risk for amputation by both overall scores, and the distributions of each score system were similar between the groups (Table II) .
Procedure. Angiographically, 81% of the lesions were TASC II category D and 19% TASC II category C overall (Table II) . The length of all the lesions was 15 to 20 cm or greater. There were far more TACII D lesion in the BP group than in the EV group (Table II) . Tibial runoff, described as the number of patent tibial vessels, was one tibial vessel in 79% of the patients and two or more in the remainder. Modified SVS runoff scores were equivalent (Table II) , and the differences between the two groups were not significant (Table II) . In contrast the pedal runoff in the EV group was significantly worse than in the BP group (Table II) . Lesions treated endovascularly underwent primary stenting with a median of three uncovered stents used. Sixty-nine percent of the bypasses were to the below-knee popliteal and remainder to the proximal tibials. Sixty-eight percent of these patients had a venous conduit, all using a single segment of great saphenous vein. The remainder had PTFE grafts. All tibials bypasses were with a venous conduit.
Outcomes. The OPG of 30-day MACEs was lower in the EV group than in the BP group (3% vs 8%; P ¼ .24), and both groups remained under the recommended OPG threshold of #10%. Presenting with rest pain (P ¼ .04), poor preoperative ambulation (P ¼ .02), and a high score on the MCRI (P ¼ .01) were correlated with the occurrence of MACE with 30 days. The 30-day MALE was significantly higher in the EV group (25%) than in the BP group (11%), and both were above the desired OPG of #9% (Table III) . Nine patients in the EV group and seven patients in the BP group who experienced a 30-day MALE had presented with rest pain. The 30-day MALE was correlated with a presentation with rest pain, endstage renal disease (ESRD), high amputation score by Finnvasc and PREVENT III, TASC II D lesions in both groups, and poor tibial runoff (<2 vessels). A prior ipsilateral endovascular procedure and lesional complication in the EV group also correlated with 30-day MALE. Eight percent of these events were major amputations in both groups to give equivalent 30-day amputation rates for EV and BP (P ¼ .96). In the EV group, 7% required a repeat endovascular procedure (eg, failure of antegrade approach, followed by a retrograde approach used), and the remainder went on to require a second bypass (all to the below-knee popliteal artery with PTFE). In the BP group, the remaining 3% required a graft thrombectomy #30 days. The 30-day amputation rate of 8% in both groups exceeded the OPG goal of #4% (Table III) . Eight patients required a 30-day amputation. All had presented with rest pain and had undergone previous endovascular interventions on the ipsilateral limb. All had one vessel tibial runoff and a poor pedal runoff and were ranked as high risk in the Finnvasc and PREVENT III scoring systems. The endovascular recanalization had failed in these patients in the EV group #30 days and they proceeded to a bypass. The reason for amputation was unremitting rest pain despite a patent bypass. In the BP group, all bypass were to a tibial vessel, and the reason for amputation was failure of a prosthetic bypass in two and continuing rest pain in the remainder. No deaths occurred #30 days in either group (Table III) . Total morbidity was 12% and 18%, respectively, for the EV and BP groups when systemic and local complications were accounted for (Table III) . Additional complications occurred at the site of intervention (lesional) in 6% of the EV group (Table III) . Hemodynamically, 87% of patients in the BP group demonstrated a rise in their ankle-brachial index/toe-brachial index of >0.15 compared with 67% in the EV group (P ¼ .01; Table IV) . This result was mirrored by symptom relief, with 84% of patients in the BP group reporting significantly improved or resolved symptoms vs 78% in EV group (P ¼ .001; Table IV ). Patients with rest pain saw the most superior symptom relief compared with those presenting with claudication. Ambulatory status at 3 months was significantly improved compared with the admission baseline in the BP group (P ¼ .004), and a positive change also occurred in the EV group but did not reach statistical significance (P ¼ .07; Tables I and IV) . There was no difference in discharge status between the groups (Table IV) .
The overall long-term mortality was high. Patient survival rates ay 5 years were 35% 6 4% for the EV group and 47% 6 8% for the BP group (P ¼ .03). Survival was negatively influenced by presenting symptoms (P ¼ .04), the presence of congestive heart failure (P ¼ .03), and estimated glomerular filtration rate of <60 mL/min/1.73 m 2 (P ¼ .04) and occurrence of MACE (P ¼ .01). The 3-year primary, assisted primary, and secondary patencies were, respectively, 25% 6 4%, 32% 6 5%, and 40% 6 7% for the EV group and 47% 6 2%, 51% 6 4%, and 63% 6 6% for the BP bypass group, which were each significantly different. Patency in the EV group was negatively influenced by the presence of diabetes and ESRD requiring hemodialysis, the length of the lesion (P ¼ .04), lesion calcification (P ¼ .03) and tibial runoff (P ¼ .01). Patency in the BP group was negative influenced by the presence of ESRD requiring hemodialysis, the conduit used (P ¼ .04 for prosthetic) and tibial runoff (P ¼ .02 for <2 tibial vessels). AFS at 3 years was 33% 6 9% for EV and 56% 6 8% for BP (P ¼ .02 ; Fig) groups, respectively. High scores on the Finnvasc (P ¼ .02) and PREVENT III (P ¼ .03) scoring systems were predictive of major amputation in both groups. On multivariate Cox proportional hazard analysis, diabetes (P ¼ .02) and poor pedal runoff (P ¼ .03) were predictive of limb loss, and improvement of hemodynamics after the intervention (P ¼ .02) was predictive of limb preservation in both groups.
Freedom from MALE at 3 years was 19% 6 8% for the EV group and 46% 6 7% for the BP group (P ¼ .04). Multivariate Cox proportional hazard analysis showed performance of EV rather than BP was associated with a higher MALE rate (P ¼ .01). Significant predictors of MALE were rest pain (P ¼ .02), TASC II lesion D (P ¼ .04), and one-vessel tibial runoff (P ¼ .02) in the EV group and were presentation with rest pain (P ¼ .02), use of a prosthetic conduit (P ¼ .043), one-vessel tibial runoff (P ¼ .02), and failure of previous endovascular intervention (P ¼ .037) on the limb in the.
Clinical efficacy at 3 years was 11% 6 9% for EV and 36% 6 8% for BP (P ¼ .04). Smultivariate Cox proportional hazard analysis were congestive heart failure (P ¼ .02), presentation with rest pain (P ¼ .046), and one-vessel tibial runoff (P ¼ .021) in the EV group and presentation with congestive heart failure (P ¼ .04), use of a prosthetic conduit (P ¼ .049), one-vessel tibial runoff (P ¼ .04), poor hemodynamic improvement (P ¼ .03), and no change in ambulatory status (P ¼ .02) in the BP group.
DISCUSSION
In this study, we report the results of a retrospective review comparing the outcomes of symptomatic femoropopliteal occlusion after redo bypass or native SFA recanalization using the OPGs laid out by the SVS. The endovascular interventions in this clinical setting carried a low MACE rate but a high MALE rate at 30 days, but the opposite was true for redo bypass surgery. In the long-term, AFS was superior in the BP group compared with the EV group. Freedom from MALE was poor after endovascular intervention. Clinical efficacy, defined as absence of recurrent symptoms, maintenance of ambulation, and limb preservation, was poor. However, when one examines the results, one cannot discount that surgeon bias, referral bias, and potential complexity caused by clinical and anatomic high risk factors may have influenced the results. An endovascular intervention was more likely in patients with a higher MCRI, and a bypass was more likely in patients with a more advanced lesion. In addition, the high use of vein would suggest this may have influenced the decision to offer a redo bypass graft. The data do not appear to suggest that runoff or risk of amputation influenced the type of intervention, but one cannot discount that there were patients who were not offered a procedure that had poor runoff or a higher risk of amputation. Importantly, most of these patients had suboptimal runoff, which is a harbinger for poor results when using either endovascular intervention or bypass. Suboptimal runoff does result in poor long-term performance. 8, 14 Consideration of recannulation of the native arterial circulation was described in a series of stand-alone studies: that graft salvage for femoral above-knee bypass grafts yielded 3-year patency rates from the time of first reoperation of 52%, whereas the 3-year patency rates were 13% for femoral below-knee and 15% for femorodistal bypasses. However, implantation of totally new grafts to a different outflow artery in these settings had 3-year patency rates of 48% and 39% for femorodistal bypasses. 21 In the Vascular Study Group of New England database, AFS at 1 year was significantly lower for patients undergoing lower extremity bypass for acute ischemia compared with patients undergoing bypass for all other indications (63% vs 77%). 22 A second report from the Vascular Study
Group of New England database demonstrated 1-year major amputation rates were significantly higher (29% vs 20%) in patients with a prior ipsilateral bypass who were undergoing lower extremity bypass for critical ischemia. Independent multivariate predictors of a higher 1-year amputation and graft occlusion rates were prior ipsilateral bypass, dialysis dependence, prosthetic conduit, and distal (tibial and pedal) bypass target. 23 The patency and AFS rates in our study were equivalent to later series and lower than in earlier series. A particular strength of our report is endovascular intervention for CTO compared with redo bypass, allowing for context. An alternative to endovascular therapy for the CTO or redo bypass surgery is CDT. Although clinical outcome data remain inconsistent, CDT remains a common technique for graft occlusion. 24 In a recent study by Comerato et al, 24 initial treatment of nonembolic acute limb ischemia with currently available CDT options was associated with greater health care resource consumption and cost compared with other initial treatment options. Kashyap et al, 25 in a study of lysis for acute ischemia, identified patients presenting with graft thrombosis were associated with poorer primary patency rates. In addition cumulative limb salvage at 24 months was 69%, with female gender and thrombolysis therapy lasting >3 days associated with an increased risk of limb loss. 25 Other authors have identified older age, ESRD, poor pedal outflow, and the presence of a synthetic graft as predictors of limb loss when thrombolysis is the primary therapy.
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CONCLUSIONS
Patients presenting with symptomatic bypass occlusion manifested by rest pain who are not considered suitable for lytic therapy should be considered for redo bypass with vein rather than native CTO recanalization. This recommendation should be tempered by the presence of a high amputation score (Finnvasc or PREVENT III), poor tibial, and pedal runoff. 
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